Sonoma Pharmaceuticals Financials
| SNOA Stock | USD 3.48 0.14 3.87% |
Sonoma |
Please note, the presentation of Sonoma Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sonoma Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sonoma Pharmaceuticals' management manipulating its earnings.
Sonoma Pharmaceuticals Stock Summary
Sonoma Pharmaceuticals competes with China Pharma, Akanda Corp, Sunshine Biopharma, Alpha Teknova, and Cannara Biotech. Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia. Sonoma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US83558L2043 |
| CUSIP | 67575P207 83558L105 83558L204 67575P306 83558L303 67575P108 |
| Location | California; U.S.A |
| Business Address | 5445 Conestoga Court, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | sonomapharma.com |
| Phone | 800 759 9305 |
| Currency | USD - US Dollar |
Sonoma Pharmaceuticals Key Financial Ratios
Sonoma Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sonoma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Sonoma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sonoma Pharmaceuticals competition to find correlations between indicators driving Sonoma Pharmaceuticals's intrinsic value. More Info.Sonoma Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sonoma Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Sonoma Pharmaceuticals Systematic Risk
Sonoma Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sonoma Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Sonoma Pharmaceuticals correlated with the market. If Beta is less than 0 Sonoma Pharmaceuticals generally moves in the opposite direction as compared to the market. If Sonoma Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sonoma Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sonoma Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Sonoma Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
About Sonoma Pharmaceuticals Financials
What exactly are Sonoma Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Sonoma Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Sonoma Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Sonoma Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Sonoma Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sonoma Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Sonoma Pharmaceuticals March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sonoma Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sonoma Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sonoma Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Sonoma Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sonoma Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.82 | |||
| Information Ratio | 0.0983 | |||
| Maximum Drawdown | 56.0 | |||
| Value At Risk | (7.04) | |||
| Potential Upside | 9.35 |
Complementary Tools for Sonoma Stock analysis
When running Sonoma Pharmaceuticals' price analysis, check to measure Sonoma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sonoma Pharmaceuticals is operating at the current time. Most of Sonoma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Sonoma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sonoma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Sonoma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |